Cargando…

Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel

OBJECTIVE: The clinical efficacy of clopidogrel in secondary prevention of vascular events is hampered by marked inter-patient variability in drug response, which partially depends on genetic make-up. The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galeazzi, Roberta, Olivieri, Fabiola, Spazzafumo, Liana, Rose, Giuseppina, Montesanto, Alberto, Giovagnetti, Simona, Cecchini, Sara, Malatesta, Gelsomina, Di Pillo, Raffaele, Antonicelli, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061429/ https://www.ncbi.nlm.nih.gov/pubmed/29936693 http://dx.doi.org/10.1007/s40266-018-0555-1

Ejemplares similares

Effects of a novel nutraceutical combination (BruMeChol™) in subjects with mild hypercholesterolemia: study protocol of a randomized, double-blind, controlled trial
por: Bonfigli, Anna Rita, et al.
Publicado: (2020)

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
por: Neubauer, Horst, et al.
Publicado: (2011)

Prognostic relevance of normocytic anemia in elderly patients affected by cardiovascular disease
por: Spazzafumo, Liana, et al.
Publicado: (2021)

Mapping the antiplatelet effects of clopidogrel and aspirin by modified thromboelastography
por: Hemlata,, et al.
Publicado: (2013)

Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers
por: Lee, Wonjae, et al.
Publicado: (2010)

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
por: Cirillo, Plinio, et al.
Publicado: (2020)

Analysis of Gastrointestinal Prophylaxis in Patients Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Morneau, Kathleen M., et al.
Publicado: (2014)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Randomized, Double-Blind, Placebo-Controlled Trial to Test the Effects of a Nutraceutical Combination Monacolin K-Free on the Lipid and Inflammatory Profile of Subjects with Hypercholesterolemia
por: Protic, Olga, et al.
Publicado: (2022)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
por: Qu, Jianyu, et al.
Publicado: (2021)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial
por: Marcantoni, Emanuela, et al.
Publicado: (2022)

Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed
por: Gosavi, Siddharth, et al.
Publicado: (2023)

Aspirin and Clopidogrel Resistance
por: Sztriha, Laszlo K., et al.
Publicado: (2004)

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
por: Bath, Philip M, et al.
Publicado: (2018)

Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Puccini, Marianna, et al.
Publicado: (2022)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
por: Mouhrach, Ismail, et al.
Publicado: (2023)

Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients
por: Ahmed, Sagheer, et al.
Publicado: (2022)

Exercise: a “new drug” for elderly patients with chronic heart failure
por: Antonicelli, Roberto, et al.
Publicado: (2016)

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
por: Mugosa, Snezana, et al.
Publicado: (2021)

Clopidogrel versus Aspirin after Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stenting
por: Sim, Doo Sun, et al.
Publicado: (2019)

Aspirin and antiplatelet treatments in cancer
por: Tao, Derrick L., et al.
Publicado: (2021)

A Randomised Controlled Trial of Triple Antiplatelet Therapy (Aspirin, Clopidogrel and Dipyridamole) in the Secondary Prevention of Stroke: Safety, Tolerability and Feasibility
por: Sprigg, Nikola, et al.
Publicado: (2008)

Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study
por: Altman, Raul, et al.
Publicado: (2012)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents
por: Giuliani, Angelica, et al.
Publicado: (2022)

Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM
por: Spazzafumo, Liana, et al.
Publicado: (2017)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Aspirin and clopidogrel resistance: methodological challenges and opportunities
por: Gasparyan, Armen Yuri
Publicado: (2010)

Aspirin/clopidogrel: Lack of efficacy: case report
Publicado: (2020)

Prophylactic Add-on Antiplatelet Therapy in Chronic Kidney Disease With Type 2 Diabetes Mellitus: Comparison Between Clopidogrel and Low-dose Aspirin
por: Dash, Amitabh, et al.
Publicado: (2013)

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
por: Bauer, Tim, et al.
Publicado: (2011)

ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel
por: Nassar, Suheir, et al.
Publicado: (2014)

Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults
por: Sridharan, Kannan, et al.
Publicado: (2016)

Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis
por: Tan, Shuai, et al.
Publicado: (2015)

Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers
por: Seo, Kwon-Duk, et al.
Publicado: (2014)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
por: Amin, Arwa M., et al.
Publicado: (2017)

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
por: Algra, Ale, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_ht137lkagnhlfd46j7sb4mhld1